Pimitespib

N/A

Report date: 2023/02/06 17:46:10
NME

Base Information

Drug NamePimitespib
Drug Alias NameJeselhyジェセリTAS-116
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHeat shock protein HSP 90-alpha inhibitorsHeat shock protein HSP 90-beta inhibitors
TargetsHeat shock protein HSP 90-betaHeat shock protein HSP 90-alpha
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungHead and Neck Neoplasms +[10] 
Global Approved IndicationsGastrointestinal Stromal Tumors
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2022/08/01
Country/TerritoryUnited StatesSingaporeTaiwan +[8] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesTaiho Pharmaceutical Co LtdOtsuka Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBushu Pharmaceuticals LtdTaiho Pharmaceutical Co LtdTaiho Pharmaceutical Of Beijing Co Ltd
Inactive CompaniesTaiho Oncology Inc
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungHead and Neck Neoplasms +[10] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG